Literature DB >> 16409175

Haemophilia in Poland.

J Windyga1, S Lopaciuk, E Stefanska, A Juszynski, D Wozniak, O Strzelecki, A B Szczepanik.   

Abstract

The primary aim of this study was to analyse the data on 2269 haemophilic patients in the Polish National Register of Inherited Bleeding Disorders -- 1953 haemophilia A patients and 316 haemophilia B patients. Haemophilia A occurred in 1512 families, haemophilia B in 240 families. In the majority of haemophilia A and B cases severe haemophilia prevailed (59.7% and 56.6% respectively). In about 50% of haemophilic patients, no family history of bleeding diathesis was reported. For haemophilia A patients the mean age was 30.9 years and for haemophilia B patients, 29.2 years. Prevalence of haemophilia in Poland is approximately 1:12 300 inhabitants (1:5600 males). The second aim was to describe the orthopaedic status of severe haemophilia patients and to relate this status to the type of replacement therapy they received prior to the study. Ninety-two severe haemophilia patients (median age 26.0 years) were enrolled in the study. Right and left knee, elbow and ankle joints were evaluated clinically using the Gilbert scale. X-ray examinations were evaluated according to the Pettersson scale. Knee joints proved to be most affected. Eighty-four patients (91.3%) reported pain. Only one scored 0 on the Gilbert scale, another on the Pettersson scale. Thirty-seven per cent of patients used orthopaedic equipment, either occasionally or constantly. Twenty-five per cent had a history of orthopaedic surgery. Thirty-eight per cent were unemployed with some form of social subvention. On-demand treatment was applied. None of the patients received primary prophylaxis. The mean consumption of clotting factor concentrates was 68 054 IU per patient during the 12 months prior to the current study. These results indicate that in Poland all severe haemophilia patients above 20 years are affected by haemophilic arthropathy.

Entities:  

Mesh:

Year:  2006        PMID: 16409175     DOI: 10.1111/j.1365-2516.2006.01188.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients.

Authors:  Patricia Pinto; Tejashree Shelar; Vidhya Nawadkar; Darshana Mirgal; Alfiya Mukaddam; Preethi Nair; Priyanka Kasatkar; Tejasvita Gaikwad; Shahnaz Ali; Anshul Jadli; Rucha Patil; Anita Parihar; Sharda Shanbhag; Bipin Kulkarni; Kanjaksha Ghosh; Shrimati Shetty
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-05       Impact factor: 0.900

2.  Co-Infection of the Hepatitis C Virus With Other Blood-Borne and Hepatotropic Viruses Among Hemophilia Patients in Poland.

Authors:  Marta Kucharska; Malgorzata Inglot; Aleksandra Szymczak; Weronika Rymer; Malgorzata Zalewska; Krzysztof Malyszczak; Urszula Zaleska-Dorobisz; Malgorzata Kuliszkiewicz-Janus
Journal:  Hepat Mon       Date:  2016-07-23       Impact factor: 0.660

3.  Perioperative Physiotherapy for Total Ankle Replacement in Patients with Inherited Bleeding Disorders: Outline of an Algorithm.

Authors:  Andrzej Kotela; Magdalena Wilk-Frańczuk; Joanna Jaczewska; Piotr Żbikowski; Paweł Łęgosz; Paweł Ambroziak; Ireneusz Kotela
Journal:  Med Sci Monit       Date:  2017-01-27

4.  Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.

Authors:  A Dmoszynska; K Kuliczkowski; A Hellmann; J Trelinski; J Kloczko; T Baglin; C Hay; D O'Shaughnessy; K Zawilska; M Makris; R Shaikh-Zaidi; E Gascoigne; C Dash
Journal:  Haemophilia       Date:  2011-03-04       Impact factor: 4.287

Review 5.  Physical and psychosocial challenges in adult hemophilia patients with inhibitors.

Authors:  Sue duTreil
Journal:  J Blood Med       Date:  2014-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.